A Phase II Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer
18 Years
N/A
Female
Metastatic Breast Cancer
Trial Information
A Phase II Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer
PROTOCOL SUMMARY
Study design: Phase II trial of monthly Doxil® and vinorelbine on day 1 and 2 in women with
metastatic breast cancer.
Treatment plan: Patients will continue therapy, until they have unacceptable toxicity or
disease progression.
Primary endpoint: Response rate
Secondary endpoints: Time to progression, overall survival and toxicity.
Additional study objectives: Evaluation of treatment-related dyspnea, with measurement of
pulse oximetry during and after drug administration, and rigorous study of patients who
experience dyspnea. Palmar-plantar erythrodysesthesia (PPE) will be treated with one of 2
randomly assigned topical salves, measuring duration and severity of symptoms.
Eligibility: Women who have had prior chemotherapy in the adjuvant or metastatic setting, or
both, up to 3 prior regimens. Patients having more than one prior regimen for metastatic
disease must have a performance status of 0 or 1; others may have 0-2. No prior Doxil® or
vinorelbine therapy. Patients are ineligible if prior anthracycline dose is greater than 400
mg/m2, or if they have primary anthracycline-refractory disease, with disease progression
during treatment or with relapse/recurrence within 6 months after last dose of
anthracycline. Patients must have normal neurologic, hematologic, renal and hepatic
functional parameters. Asymptomatic brain metastases are permissible.
Treatment plan: Doxil® 40 mg/m2 IV infusion over 60 minutes on day 1 Vinorelbine 15 mg/m2
IV over 6 minutes on days 1 and 2 Dexamethasone 4 mg IV or 8 mg po (Doxil® pretreatment)
Heparin 5000 U IV (Vinorelbine pretreatment) Pyridoxine (vitamin B6) 200 mg po qd Repeat
every 28 days.
Supportive measures:
For anemia (hematocrit < 35): Procrit® 40,000 U q wk For neutropenia (ANC < 1,000/mm3 ):
Prophylactic antibiotics (Cipro® or Septra®) For all cycles after neutropenic
fever/infection or grade 3-4 stomatitis: Prophylactic Neulasta® 6 mg SQ on day 3 (This
intervention may be adopted for all patients, all cycles, if 2 of the first 4 patients
enrolled need it.) For PPE: randomize between 2 topical salves and document duration and
severity of sx
Dose adjustments: Subsequent cycles are given on day 29 or after recovery or to grade 0-1
toxicity, with no more than 3 weeks delay. Reduce dose of both drugs by 25% if grade 3 or 4
stomatitis or palmar-plantar or grade 4 thrombocytopenia. Reduce dose of Doxil® ONLY by
50-75% if abnormal bilirubin, alkaline phosphatase and/or ALT, AST (appendix 14.3)
Inclusion Criteria:
- Patients must be informed of the investigational nature of this study and must give
and sign informed consent in compliance with federal and institutional guidelines.
- Women 18 years or older with biopsy proven advanced breast cancer.
- Patients with reproductive potential must use an adequate contraceptive method (e.g.,
abstinence, intrauterine device, oral contraceptives, barrier device with spermicide,
or surgical sterilization) during treatment and for three months after completing
treatment.
- Performance status (PS) 0-2 (ECOG). PS must be 0-1 if patient has had more than one
prior regimen for metastatic disease or more than 2 prior regimens, including
adjuvant and metastatic.
- Measurable disease by RECIST criteria, with baseline staging completed within 14 days
of registration.
- At least two weeks post surgery and three weeks from completion of irradiation and
recovered from toxicities associated with these treatments.
- Psychological, family, social and geographical conditions allowing weekly medical
follow up during chemotherapy are required.
- Preregistration blood work must include complete blood counts with differential, and
blood chemistries including serum bilirubin, GGT, LDH, SGOT, SGPT, alkaline
phosphatase, creatinine, and tumor markers, CEA and CA 27-29. Patients must have:
- Absolute neutrophil count (ANC) >1,500/mm3
- Platelet count >100,000/mm3
- Hemoglobin > 8.0 g/dl
- Serum creatinine < 2.5 mg/dl (< 200 mol/L)
- Serum bilirubin < the upper limit of normal (ULN)
- SGOT and SGPT or AST and ALT < 2.0 x ULN
- Alkaline phosphatase < 2.0 x ULN, except if attributed to tumor
- Life expectancy > than 12 week.
Exclusion Criteria:
- Prior Doxil® or vinorelbine
- Cumulative anthracycline dose exceeding 400 mg/m2 anthracycline
- Primary anthracycline refractory disease, ie. disease progression during treatment or
relapse/recurrence within 6 months after last dose of anthracycline
- If PS 0-1, more than 3 prior chemotherapy regimens, including adjuvant and metastatic
- If PS 2, more than 1 prior regimen for metastatic disease or more than 2 prior
chemotherapy regimens, including adjuvant and metastatic
- Hormone therapy including aromatase inhibitors within 2 weeks of baseline
- Pregnant or lactating women. Women of reproductive potential must have a negative
pregnancy test and must agree to use an effective contraceptive method
- Prior history of cardiac disease, with New York Heart Association Class II or
greater, or clinical evidence of congestive heart failure
- Symptomatic brain metastasis
- Past medical history of severe hypersensitivity reaction to conventional formulation
of doxorubicin HCL or the components of Doxil® or vinorelbine
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Response rate
Principal Investigator
Leslie R Laufman, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Hematology Oncology Consultants, Inc
Authority:
United States: Institutional Review Board
Study ID:
DO03-21-005
NCT ID:
NCT00159094
Start Date:
October 2003
Completion Date:
Related Keywords:
- Metastatic Breast Cancer
- Breast Neoplasms
Name | Location |
|---|---|
| Hematology Oncology Consultants, Inc | Columbus, Ohio 43235 |
